Enovis (NYSE:ENOV) Cut to “Hold” at Wall Street Zen

by · The Markets Daily

Wall Street Zen downgraded shares of Enovis (NYSE:ENOV – Free Report) from a buy rating to a hold rating in a report issued on Sunday,Wall Street Zen reports.

ENOV has been the topic of several other research reports. BMO Capital Markets set a $27.00 target price on Enovis in a report on Tuesday, September 1st. Canaccord Genuity Group decreased their price target on Enovis from $50.00 to $45.00 and set a “buy” rating for the company in a report on Monday, August 17th. Evercore set a $32.00 price objective on Enovis in a research report on Monday, July 6th. Wells Fargo & Company lowered their price objective on Enovis from $39.00 to $33.00 and set an “overweight” rating for the company in a research report on Wednesday, September 2nd. Finally, Weiss Ratings upgraded Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Enovis presently has a consensus rating of “Moderate Buy” and an average target price of $40.38.

Read Our Latest Report on Enovis

Enovis Stock Performance

Shares of Enovis stock opened at $18.36 on Friday. The business has a 50-day simple moving average of $24.25 and a 200-day simple moving average of $23.78. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.00 and a current ratio of 1.98. Enovis has a one year low of $17.30 and a one year high of $34.28. The company has a market cap of $1.06 billion, a PE ratio of -0.95 and a beta of 1.31.

Enovis (NYSE:ENOV – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The firm had revenue of $582.78 million for the quarter, compared to analysts’ expectations of $581.84 million. During the same quarter last year, the company earned $0.79 earnings per share. The firm’s revenue was up 3.2% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities research analysts forecast that Enovis will post 3.15 EPS for the current fiscal year.

Insiders Place Their Bets

In other Enovis news, insider Oliver Engert acquired 5,140 shares of the company’s stock in a transaction on Thursday, September 3rd. The shares were bought at an average cost of $19.46 per share, for a total transaction of $100,024.40. Following the completion of the purchase, the insider owned 61,238 shares in the company, valued at $1,191,691.48. This trade represents a 9.16% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Damien Mcdonald bought 13,035 shares of Enovis stock in a transaction dated Friday, September 4th. The stock was acquired at an average cost of $19.15 per share, with a total value of $249,620.25. Following the completion of the acquisition, the chief executive officer directly owned 247,077 shares of the company’s stock, valued at approximately $4,731,524.55. The trade was a 5.57% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders acquired 23,293 shares of company stock worth $449,599. 2.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of ENOV. Paradigm Capital Management Inc. NY lifted its holdings in shares of Enovis by 70.2% during the first quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock worth $40,420,000 after purchasing an additional 732,917 shares during the period. River Road Asset Management LLC raised its position in Enovis by 3.2% during the 4th quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock worth $39,621,000 after buying an additional 46,289 shares during the last quarter. Private Management Group Inc. raised its position in Enovis by 38.8% during the 2nd quarter. Private Management Group Inc. now owns 1,365,082 shares of the company’s stock worth $28,257,000 after buying an additional 381,705 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in shares of Enovis by 38.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 1,045,360 shares of the company’s stock worth $24,430,000 after acquiring an additional 287,687 shares during the period. Finally, Royce & Associates LP lifted its stake in shares of Enovis by 14.6% in the 4th quarter. Royce & Associates LP now owns 826,848 shares of the company’s stock worth $22,027,000 after acquiring an additional 105,608 shares during the period. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Company Profile

(Get Free Report)

Enovis Corporation is a medical technology company that develops, manufactures and distributes products designed to improve patient mobility, support recovery and restore physical function. Its offerings serve orthopedic, sports medicine, rehabilitation and pain-management markets, with products used by healthcare professionals, athletes and patients.

The company’s product portfolio includes orthopedic braces and supports, surgical solutions, cold and compression therapy systems, rehabilitation equipment, physical therapy devices and recovery technologies.

Featured Articles